KLRK1 and neoplasm: Several potential mechanisms have been proposed, including tumour‐derived soluble NKG2D ligands down‐regulating NKG2D expression on cytolytic cells, and sustained NKG2D ligands expression by tumours eliciting NKG2D down‐regulation which resulting in impairment of NKG2D‐dependent cell activation 3, 4.